- Details
- Javid Moslehi joins Alicia Morgans in a conversation on the cardiovascular health of cancer patients. Javid Moslehi's laboratory focuses on mechanistic understanding of cardiovascular toxicities that result from novel “targeted” cancer therapies. In this conversation, they discuss the cardiovascular toxicities associated with androgen deprivation therapy (ADT) and the physiologic mechanisms and ma...
|
- Details
- Darren Feldman joins Alicia Morgans to discuss clinical trials and the treatment of testicular cancer. Dr. Feldman provides an overview of the TIGER trial, an international randomized, multicenter open-label phase III trial. The study is an international collaboration with European sites. Collaborators on the study include the National Cancer Institute, the European Organization for Research and T...
|
- Details
- Matt Cooperberg hosts a discussion with Peter Carroll and Laurence Klotz examining their roles in the progress of active surveillance for low-risk prostate cancer and how they incorporate this treatment into clinical practice. They discuss the change in the field from over-detection and overtreatment where radiation and surgery were the primary treatment options to the evolution of active surveill...
|
- Details
- Louise Emmett presents on the modulation of prostate-specific membrane antigen (PSMA) expression by androgen deprivation therapy (ADT). The study is comprised of serial PSMA PET in men with either hormone-sensitive or castrate-resistant prostate cancer commencing androgen blockade. PSMA may be targeted for either diagnostic and therapeutic purposes in the management of prostate cancer. Dr. Emmett...
|
- Details
- Hossein Jadvar presents on the use of sodium fluoride and radium-223 as a theranostic pair in the treatment of patients with metastatic prostate cancer. 18 F-sodium fluoride has experienced a remarkable recent renaissance in the management of neuroendocrine tumors and prostate cancer. Dr. Jadvar presents this information during the annual meeting of the Society of Nuclear Medicine and Molecular Im...
|
- Details
- (Length of Video: 4 min) Video: Percutaneous Diverticula (PERC-TIC) technique Read: Comparative study of percutaneous tic technique versus standard percutaneous nephrolithotomy. Read: Reviewing Percutaneous Nephrolithotomy with PERC-TIC Technique - Beyond the Abstract
|
- Details
- Neal Shore joins Alicia Morgans in a discussion on the optimal timing to use radium-223 (Xofigo®) in metastatic castration-resistant prostate cancer (mCRPC). Together they discuss the window of opportunity for administering radium-223 and what we have learned from the ALSYMPCA and ERA-223 trials. Dr. Shore recaps how radium-223 is being used prior to docetaxel and how it is being layered with an a...
|
- Details
- Ashish Kamat invites Alison Birtle to share a review of a Phase III Randomized Trial of Perioperative Chemotherapy versus Surveillance in Upper Tract Urothelial Carcinoma (UTUC) POUT study. The POUT study sought to answer the basic question, does adjuvant chemotherapy reduce the risk of relapse for upper tract urothelial carcinoma (UTUC) patients who've had a potentially "curative," nephroureterec...
|
- Details
- Alicia Morgans is joined by Peter O’Donnell and Jonathan Rosenberg to discuss enfortumab vedotin (EV). This offers a new mechanism of action and is the first antibody-drug conjugate (ADC). This represents a targeted therapy and was studied in metastatic urothelial carcinoma. In reviewing the clinical data and side effects of the drug, the three clinicians highlight the effectiveness and tolerabili...
|
- Details
- Andrei Iagaru speaks on non-PSMA based theranostics in prostate cancer. Dr. Iagaru covers gastrin-releasing peptide receptors, part of the bombesin family, which are overexpressed in many cancers including prostate cancer. Targeting tumor-expressed receptors using selective molecules for diagnostic, therapeutic or both diagnostic and therapeutic purposes is a promising approach in oncological appl...
|
